{"organizations": [], "uuid": "37ad4d6431dcaa98adb1012cca0d2d014a55c877", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-prometic-reports-positive-clinical/brief-prometic-reports-positive-clinical-data-from-its-intravenous-immunoglobulin-pivotal-phase-3-trial-idUSASC09Y5K", "country": "US", "domain_rank": 408, "title": "BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T13:46:00.000+03:00", "replies_count": 0, "uuid": "37ad4d6431dcaa98adb1012cca0d2d014a55c877"}, "author": "", "url": "https://www.reuters.com/article/brief-prometic-reports-positive-clinical/brief-prometic-reports-positive-clinical-data-from-its-intravenous-immunoglobulin-pivotal-phase-3-trial-idUSASC09Y5K", "ord_in_thread": 0, "title": "BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "prometic life sciences inc", "sentiment": "none"}, {"name": "trial reuters", "sentiment": "none"}, {"name": "ivig", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30, 2018 / 10:50 AM / Updated 9 minutes ago BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial Reuters Staff\nApril 30 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL\n* PROMETIC LIFE SCIENCES INC - PIVOTAL CLINICAL TRIAL MEETS PRIMARY AND SECONDARY ENDPOINTS\n* PROMETIC LIFE SCIENCES INC - CLINICAL DATA DEMONSTRATES COMPARABLE EFFICACY TO COMMERCIALLY-APPROVED DRUG\n* PROMETIC LIFE SCIENCES INC - PROMETIC IVIG’S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES\n* PROMETIC LIFE SCIENCES INC - PROMETIC IVIG’S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES\n* PROMETIC LIFE SCIENCES INC - OVERALL PROMETIC IGIV 10% APPEARED TO BE WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY SBIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-30T13:46:00.000+03:00", "crawled": "2018-04-30T14:07:13.006+03:00", "highlightTitle": ""}